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Abstract
Non-alcoholic fatty liver disease (NAFLD) is a common chronic liver disease which represents a wide spectrum of
hepatic damage. Several studies have reported that NAFLD is a strong independent risk factor for coronary artery
disease (CAD). And patients with NAFLD are at higher risk and suggested undergoperiodic cardiovascular risk
assessment. Cardiovascular disease (CVD) is responsible for the main cause of death in patients with NAFLD, and
is mostly influenced by genetic factors. Both NAFLD and CAD are heterogeneous disease. Common pathways involved in
the pathogenesis of NAFLD and CAD includes insulin resistance (IR), atherogenic dyslipidemia, subclinical inflammation,
oxidative stress, etc. Genomic characteristics of these two diseases have been widely studied, further research about the
association of these two diseases draws attention. The gene polymorphisms of adiponectin-encoding gene
(ADIPOQ), leptin receptor (LEPR), apolipoprotein C3 (APOC3), peroxisome proliferator-activated receptors (PPAR),
sterol regulatory elementbinding proteins (SREBP), transmembrane 6 superfamily member 2 (TM6SF2), microsomal
triglyceride transfer protein (MTTP), tumor necrosis factors-alpha (TNF-α) and manganese superoxide dismutase (MnSOD)
have been reported to be related to NAFLD and CAD. In this review, we aimed to provide an overview of recent
insights into the genetic basis of NAFLD and CAD.
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Background
Non-alcoholic fatty liver disease (NAFLD) is recognized
as a major public health problem in both developing and
developed countries. It is the most common form of
liver disease, and represents a wide spectrum of hepatic
damage ranging from simple steatosis and non-alcoholic
steatohepatitis (NASH) to advanced fibrosis and cirrho-
sis. NAFLD is recognized as the hepatic manifestation of
metabolic syndrome (MS), which major components are
insulin resistance (IR), atherogenic dyslipidemia, abdom-
inal obesity, and hypertension [1]. MS is a lethal endo-
crinopathy involving a chain of systemic disorders such
as abdominal obesity, glucose intolerance or diabetes
mellitus (DM), dyslipidemia, hypertension and CAD.
Nowadays many epidemiological and clinical studies are
focused on the association between NAFLD and CAD
[2, 3]. Several studies have reported that NAFLD was a
strong independent risk factor for CAD in different
racial group and with different research methods [4–6].
Meanwhile, a series of studies showed that in NAFLD
patients, CAD was the leading cause of death, among
the common causes of death after all of the hepatic and
extra hepatic malignancy combined [7, 8]. Occurrences
of these two diseases are both the result of interactions
between multiple genetic variations and environmental
factors although a full understanding of pathogenesis
has not yet been elucidated. Genetic polymorphisms are
reported to influence predisposition of individuals to
NAFLD and CAD [9, 10]. Moreover, recent progresses
in genomics provide new knowledge of both normal and
disease states for precision medicine and systems thera-
peutics. Therefore, this review aim to summarize the
recent advances of correlated genes and the promoting
mechanism for NAFLD and CAD, and to assess the
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possible implication of these polymorphisms on disease
morbidity and severity in those patients. It will aid in the
development of genes based therapeutic strategies to
combat NAFLD and CAD, and could lead to more effect-
ive precision medicine to identify the correct strategies for
each individual in order to maximize therapeutic effect
and minimize the occurrence of adverse reactions.
Adiponectin-encoding gene (ADIPOQ)
Adiponectin-encoding gene, ADIPOQ, located on chromo-
some 3q27, encoding adiponectin protein which is an
adipocyte-derived hormone with anti-atherogenic, anti-
diabetic and anti-inflammatory properties. In liver, adipo-
nectin protein attenuates insulin resistance by increasing
insulin sensitivity. Besides, adiponectin increases endothe-
lial nitric oxide (NO) secretion and inhibits monocyte
adhesion and smooth muscle cell proliferation in the
vascular wall [11, 12]. In NAFLD patients, adiponectin
systemic levels is decreased [13]. Adiponectin rs266729
(−11377C/G) polymorphism might be a candidate gene,
which determines the susceptibility to NAFLD [14]. A
study in Indian patients showed an association of two
functional polymorphisms, rs266729 and rs2241766
(+45 T/G) of ADIPOQ with the presence and severity
of NAFLD, the presence of G allele at position −11377
correlated with necro-inflammatory grade and at pos-
ition +45 resulted in reduced plasma adiponectin levels
in patients suggesting the functional relevance of these
polymorphisms in NAFLD pathogenesis and progression
[15]. G allele of rs266729 is associated with hypoadiponec-
tinemia, and low serum adiponectin level may precipitate
liver steatosis in patients with type 2 diabetes, therefore
gene polymorphism of adiponectinrs266729 is associated
with the risk of NAFLD [16]. ADIPOQ expression de-
creases significantly in epicardial adipose tissue and
paracardial adipose tissue in MS patients with CAD
[17]. Foucan L. et al. (2010) showed that in Afro-
Caribbean patients with type 2 diabetes, rs2241766 was
associated with CAD under a dominant model [18]. A
meta-analysis showed that the associations between
rs266729, rs2241766 and rs1501299 (+276G > T) in the
ADIPOQ and CVD were significant but weak. The
rs2241766 G allele and rs266729 G allele increase risk
of CVD, while the rs1501299 T allele decreases [19].
ADIPOQ rs1501299 is association with CAD, and the
SNP has different gender dependent effect on adipo-
nectin levels and the lipoprotein metabolism, consider-
ing the detrimental effect that the rare homozygous
genotype (TT) was associated with higher levels of
total cholesterol (TC) and low density lipoprotein chol-
esterol (LDL-C) compared to common homozygous
genotypes (GG) and heterozygous, and the polymorph-
ism influence on the levels of biochemical markers was
independent of adiponectin circulating level [20, 21].
Leptin receptor gene (LEPR)
Leptin exerts its physiological action through the leptin re-
ceptor (LepR) which is encoded by a single gene on the
chromosome 1p31, leptin receptor gene (LEPR). The poly-
morphism of LEPR 3057G >A (rs1805096) probably con-
tributes to the onset of NAFLD by regulating lipid
metabolism and affecting insulin sensitivity [22]. Lys656Asn
(rs8179183) polymorphism of LEPR is associated with insu-
lin resistance and glucose levels in patients with NAFLD
[23]. LEPR polymorphism rs1137101, which is responsible
for a Gln223Arg change at the protein level is associated
with TC, high-density lipoprotein cholesterol (HDL-C) and
LDL-C levels in Japanese men [24]. Polymorphisms of
LEPR Gln223Arg (G/G) is the risk factors in NAFLD, and
the significant interactions between genetic polymorphisms
of Gln223Arg added the risk of NAFLD [25]. Gln223Arg
polymorphism in the LEPR is associated with an increased
risk of familial combined hyperlipidemia which is associ-
ated with premature CVD mediated by low HDL-C [26].
LEPR rs1137100 is associated with increased risk of
NAFLD and NASH. And it was also associated with
simple steatosis and NASH without significant fibrosis
[27]. A Japanese study in obese children showed a sig-
nificantly lower total and LDL cholesterol in subjects
with GG genotype [28]. A single nucleotide polymorph-
ism rs1137100 of LEPR results in Lys109Arg change at
the protein level and this has been shown to associate
with several risk factors for CVD such as body mass
index (BMI), systolic blood pressure (SBP), impaired glu-
cose tolerance and insulin sensitivity [29–31]. In Japanese
obese children, the individual with Arg109 is association
with serum lipids [28]. Carriers of the Arg109Arg geno-
type or some other polymorphism linked to it seem to be
protective from cardiovascular events as well as from total
mortality independently of the traditional CAD risk fac-
tors [32].
Apolipoprotein C3 gene (APOC3)
Apolipoprotein C3 gene (APOC3) is located on chromo-
some 11q23. Apolipoprotein C3 protein is mainly syn-
thesized in the liver and to some extent in the intestine,
and it is a component of triglyceride (TG)-rich lipopro-
teins and HDL. APOC3 gene is involved in transport
and clearance of chylomicron remnants, and very-low-
density lipoprotein (VLDL) and HDL from the blood-
stream [33, 34]. A prospective case–control study in the
southern Han Chinese population showed that subjects
carrying the C allele (TC or CC) of apolipoprotein
gene developed insulin resistance (IR) more com-
monly, and it was in agreement with that found in the
Indian population [35]. The polymorphisms −482 C/T
(rs2854117) and −455 T/C (rs2854116) in APOC3 were
associated with NAFLD and IR [35]. The -455 T > C
conversion is located in a putative insulin-response
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element of APOC3, which is associated with plasma
TG levels [36–38]. A prospective case–control study
involving 300 NAFLD patients and 300 healthy con-
trols indicated that APOC3 rs2854116 genetic varia-
tions involved in the susceptibility to develop NAFLD,
IR, hypertriglyceridemia, and low HDL in the Southern
Chinese Han population [39]. A meta-analyses of 20
studies with 15,591 participants found that APOC3 Sst
I and rs2854116 polymorphisms might be associated
with the risk of CAD [40]. Ding Y. et al.(2012) indicated
that the minor alleles of APOC3 -455 T/C polymor-
phisms were closely associated with acute coronary
syndrome, which is a severe type of CAD, and the C
allele was associated with higher TG and lower HDL
cholesterol [41]. Thus, the APOC3 might contribute to
an increased risk of CAD as a result of its effect on
lipid metabolism. Polymorphic variants prevent insulin
binding, promoting the transcription and the synthesis
of APOC3. As a result, the level of circulating APOC3
increases and acts as alipoprotein lipase inhibitor, lead-
ing to decreased clearance of TG-rich particles, which
ultimately result in hypertriglyceridemia [42, 43]. The
circulating TG-rich particles are preferentially taken up
by the liver by means of a receptor-mediated process
[44–46], which results in NAFLD and hepatic IR.
Whereas a study in the Chinese Han population suggested
that the two genetic variants (T -455C at rs2854116 and
C-482 T at rs2854117) in the APOC3 were not associated
with NAFLD risk, even did not contribute to the inter-
individual differences in lipid profiles, insulin resistance,
obesity, oxidative stress and susceptibility to NAFLD [47].
A case–control study found that the APOC3 3238G al-
lele was significantly associated with increasing plasma
TG levels and VLDL-C levels and enhanced risk of
CAD via lipid metabolism [48].
Peroxisome proliferator-activated receptors gene
(PPAR)
There are three members of the PPAR family each encoded
by a different gene: PPAR (NR1C1), PPAR (NR1C3),
and PPAR (NP1C2). Carriers of the PPARγ Ala allele
showed increased resistance to the development and
progression of NAFLD by resisting oxidative stress
[49, 50]. A Meta-analysis demonstrated a protective role
for the Ala allele of the PPARγ Pro12Ala (rs1801282) poly-
morphism in NAFLD risk [51], and rs1801282 poly-
morphism is associated with susceptibility to NAFLD
in East Asians, but not in European populations [51].
Domenici F. A. et al. (2013) showed that 12 Ala allele
of PPARγ was less prevalent among NASH patients
than the healthy volunteers group. There were no asso-
ciations among PPARγ SNPs (rs1801282) and clinical,
laboratorial and histological parameters in NAFLD pa-
tients, suggest that the SNP rs1801282 may result in
protection against liver injury [52]. Leu162Val (rs1800206)
PPARα SNP may be involved in the progression of
NAFLD as the carriers have more advanced fibrosis [52].
While Wang J. et al. (2013) suggested that rs1801282
polymorphism of PPARγ was not associated with
NAFLD risk in both Asian and Caucasian descents
from a meta-analysis [53]. A study reported that
rs1800206 in PPARα was significantly associated with
Lipoprotein (a) (Lp(a)) which is a LDL-like particle
that can risk atherosclerosis independently and thus is
the risk factor of CAD. And provide an evidence PPAR
α/γ may influence the risk of dyslipidemia and cardio-
vascular diseases (CVD) via Lp (a) [54, 55]. The Ala 12
Ala genotype of the PPARγ2 may decrease the number
of diseased vessels and the severity of CAD, which
could be because of a direct anti-atherogenic effect of this
polymorphism as well as an indirect effect through its
association with a lower level of inflammatory parame-
ters and IR [56]. SNP rs3856806 (also termed C161T or
C1431T) in the PPARγ was significantly associated with
fasted serum lipid profile in individuals with angio-
graphically defined CAD since accumulating data sup-
port the role of PPARγ polymorphisms in CAD [57].
Wan J. et al. (2010) indicate that the PPARγ rs3856806
polymorphism may reduce the risk of severe atherogen-
esis by modulation of adipose metabolism in Chinese
patients with CAD [58]. We have previously demon-
strated that the SNP rs3856806 was associated with a
higher susceptibility to NAFLD through the adiponec-
tin pathway [59, 60].
Sterol regulatory elementbinding proteins
(SREBPs) / sterol regulatory elementbinding
transcription factors (SREBFs) Gene
Three isoforms of SREBPs are encoded by two genes,
SREBP-1 (SREBF-1) and SREBP-2 (SREBF-2). SREBP-1
target genes are involved in cholesterol biosynthesis,
unsaturated fatty acid biosynthesis, triglyceride biosyn-
thesis, phospholipid synthesis and lipid uptake [61, 62].
The SREBF-1c rs11868035 polymorphism is associated
with increased risk of developing NAFLD with more
severe liver histology and derangement in glucose and
lipoprotein metabolism, which contribute to the pres-
entation and natural history of NAFLD [63]. SREBP-1c
modulates the genetic susceptibility to the whole
spectrum of health-related risk in NAFLD by exten-
sively affecting multiple metabolic steps at hepatic and
extra-hepatic sites. The SNP rs11868035, which is associ-
ated with impaired glucose homeostasis and lipoprotein
and adiponectin responses to fat ingestion, was correlated
with severity of steatosis and necro-inflammation and the
presence of NASH [63]. And associated with CAD risk by
modulating the changes in endothelial adhesion molecules
[64, 65]. SREBP-2 encoded by a separate gene on human
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chromosome 22q13, which plays an important role in
the maintenance of lipid homeostasis by stimulating the
expression of genes correlated with the cholesterol bio-
synthetic pathways [66, 67]. Activation of the SREBP-2
may play a critical role in enhancing cholesterol uptake
and biosynthesis, and can be directly involved in the
regulation of cholesterol metabolism in cells, thereby
maintaining cholesterol homeostasis [68]. In recent
years, some studies have shown that genetic polymor-
phisms of SREBP-2 have a significant effect on the
development of fatty liver disease, IR, and may result in
hypertriglyceridemia [69, 70]. A case–control study in a
Han Chinese population provided evidence that the GG
genotype and G carrier (CG + GG) of rs2228314 G > C
polymorphism in SREBP-2 may increase the risk of
NAFLD. Thus, SREBP-2 rs2228314 G > C polymorph-
ism may be a potential biomarker for NAFLD [71]. A
study from Eastern China manifests that rs2228314 has
no association with the risk of premature CAD nor
extent of coronary lesions [72]. Further studies are re-
quired in this field. The C allele and the G/C genotype
of SREBP-2 rs2228314 were associated with increased
risk of NAFLD in Asian Indians. As the G/C genotype
of SREBP-2 is significantly associated with Serum levels
of TG, elevated CRP, fasting insulin and homeostasis
model assessment for insulin resistance levels, it can be
a potential explanation for the close relationship be-
tween IR, TG, CRP and SREBP-2 polymorphism [73].
The functional SNP rs133291 C/T in the SREBF-2
gene has been linked to serum LDL cholesterol [74].
SREBF-1c SNPs and SREBF-2 SNPs predicted the 7-
year incidence of NAFLD and diabetes and endothelial
dysfunction markers at the end of follow-up in nonobese,
nondiabetic, insulin-sensitive subjects without metabolic
syndrome at baseline. In biopsy-proven NAFLD patients,
SREBF-2 predicted the presence of NASH and extensively
affected tissue insulin sensitivity, pancreatic β-cell func-
tion, and lipoprotein and adipokine responses to fat in-
gestion. The SREBF-1c SNP, which is associated with
impaired glucose homeostasis and lipoprotein and adi-
ponectin responses to fat ingestion, was correlated with
the severity of steatosis and necro-inflammation and
the presence of NASH [63, 64].
Transmembrane 6 superfamily member 2 gene
(TM6SF2)
TM6SF2 (rs58542926 c.449 C > T) at the 19 p13.11 locus
was associated with hepatic steatosis individuals geno-
typed using a human exome chip [75]. A exome-wide
association studies identified the rs58542926 C > T gen-
etic variant of the TM6SF2 gene, which encodes the
E167K amino acidic substitution, as a determinant of
hepatic TG content, serum aminotransferases, and lower
serum lipoproteins [75, 76]. A case–control study in a
community-based Han Chinese population highlight a
missense variant in TM6SF2 rs58542926 is significantly
contributes to increased NAFLD risk in Chinese popula-
tion, independent of the Patatin-like phospholipase
domain-containing 3 gene rs738409 and neurocan gene
rs2228603 polymorphisms, but whether it is also in-
volved in NAFLD disease progression and severity
needed further investigation [77]. Dongiovanni P. et al.
(2015) suggested that carriers of E167K had a lower
prevalence of plaques which is associated with risk fac-
tors for atherosclerosis, this protective effect of E167K
against carotid atherosclerosis remained significant after
adjustment for risk factors and NASH. The carriers have
lower serum, and the inhibition of VLDL secretion from
the liver protects against CVD, but at the cost of an in-
creased risk of severe liver disease [78]. A mata-analysis
showed that although TM6SF2 rs58542926 T allele con-
fers protection against CVD at the expense of higher
risk for NAFLD, it does not explain the link between
these two complex diseases [79].
Microsomal triglyceride transfer proteingene
(MTP/MTTP)
Act as a key role in lipid metabolism, MTP’s functional
polymorphisms have previously been investigated. A recent
meta-analysis indicates that MTP -493G >T (rs1800591)
polymorphisms may contribute to the susceptibility to
NAFLD patients. While MTP rs1800591 polymorphism
may be a valuable and practical biomarker for early detec-
tion of NAFLD [80]. In the Japanese population, a study
showed that the-493 G-allele frequency was significantly
higher in patients with biopsy-proven NASH than in the
healthy control group, and the GG genotype in NASH pa-
tients predicted more severe steatosis [81]. However, the
results regarding it are inconsistent. A study in a Brazilian
population showed that there was no significant associ-
ation between the rs1800591 polymorphism and NAFLD
[82]. Peng X. E. et al. (2014) showed that MTP rs1800804
(−164 T/C) was associated with an increased risk of
NAFLD and the level of TG was significantly lower in con-
trols with the rs1800804 (−164 C) risk allele [83]. MTP
rs1800804 functional polymorphism and total cholesterol
levels have an interaction. Thereby risk allele carriers with
low cholesterol levels may be predisposed to an increased
risk of developing CVD, which seems to be abolished
among risk allele carriers with high cholesterol levels.
Tumor necrosis factors-alpha gene (TNF-α)
Human TNF-α gene is located on chromosome 6p21.3.
The protein it codes acts as a biomarker of systemic in-
flammation which contributes to IR via multiple direct
endocrine and indirect modulatory effects of the genes
involved in glucose and lipid metabolism [84, 85], and
promotes inflammatory response to injury and regulates
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IR through insulin signal transduction pathways in the
liver [86]. Previous studies have shown the association
between the TNF-α polymorphisms and the risk of
NAFLD, especially in Chinese origin patients. G/A vari-
ant at the TNF-α -238 increased susceptibility to
NAFLD [60]. A study showed that TNF-α G to A poly-
morphism at position −238 was significantly associated
with CAD and that the −238 A allele carriers exhibited
an increased risk of developing CAD in Koreans, and
therefore this allele could be used as a predictor for
CAD in Koreans [87]. However, different ethnicity,
phenotype, environment and other factors may have
different results [88–91]. Variant at TNF-α -308 was
notrelevant to NAFLD [60]. However, Hussain S. et al.
(2015) showed that TNF-α -308 G > A polymorphism is
significantly associated with CAD in the Pakistani
population [92]. Recently, Chinese researchers provided
preliminary evidence support the association between
presence of a TNF-α -238 polymorphism and the develop-
ing of CAD in NAFLD patients of Chinese Han origin.
They suggested that TNF-α -238 GA genotype may in-
crease the risk for CAD in NAFLD patients. TNF-α -308
GA heterozygote genotype was positively associated with
elevated levels of TG in NAFLD patients with CAD. Then
obtained the conclusion that TNF-α -308 GA genotype
plays a crucial role in the development of CAD in NAFLD
patients [93].
Manganese superoxide dismutase gene
(MnSOD/SOD2)
Manganese superoxide dismutase (MnSOD) is an im-
portant antioxidant enzyme. There are data indicate that
low MnSOD in rodent models of NAFLD may contrib-
ute to increased oxidative stress, other studies describe
raised levels of this enzyme in NAFLD [94–96]. A case–
control study and a meta-analysis highlight the mutant
genotypes of TC + CC of C47T (rs4880) polymorphism
in SOD2 had a significant effect on the reduced of CAD
risk [97]. Takami Y. et al. (2010) showed that systemic
MnSOD protein is significantly higher in NASH patients
than in steatotic patients and healthy controls [98]. A
case–control and intra-familial allele association studies
prove the evidence that carriage of the rs4880 poly-
morphism involved in determining the susceptibility to
oxidative stress and fibrogenesis, respectively, have been
associated with the severity of liver fibrosis in adults and
children with NAFLD [99].
Conclusion
NAFLD and CAD has been a major public health prob-
lem affect millions of individuals worldwide. These two
diseases are both recognized as the consequence of a
complex interplay between genetics, diet and environ-
ment although a full understanding of pathogenesis has
not yet been elucidated. Recent studies on the genetic
polymorphisms association between NAFLD and CAD
may provide a new prospective to the diagnosis, preven-
tion and treatment of these two diseases. The role of
genetic screening for NAFLD and CAD, while on the
cusp, is still premature, further research are needed to
exploring the mechanisms underlying this. In future, treat-
ment would be more individualized and approaching to
precision medicine depending on the reveal of these
underlying mechanisms.
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